Regulus Therapeutics Inc.

NASDAQ:RGLS

1.47 (USD) • At close November 8, 2024
Bedrijfsnaam Regulus Therapeutics Inc.
Symbool RGLS
Munteenheid USD
Prijs 1.47
Beurswaarde 96,234,873
Dividendpercentage 0%
52-weken bereik 1.08 - 3.79
Industrie Biotechnology
Sector Healthcare
CEO Mr. Joseph P. Hagan M.B.A.
Website https://www.regulusrx.com

An error occurred while fetching data.

Over Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport

Vergelijkbare Aandelen

Microbot Medical Inc. logo

Microbot Medical Inc.

MBOT

1.02 USD

Psychemedics Corporation logo

Psychemedics Corporation

PMD

2.34 USD

Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA

2.54 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

13.31 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)